While the latter generally correlates well with SETD2 mutation status defined using a single region of the tumor, there are limits to the association, indicating that addition of H3K36me3 IHC to routine pathologic analysis would add value to mutation screening. The gene discussed is SETD2; the disease is neoplasm.